• EBITDA guidance achieved, with 8% revenue and EBITDA growth
• Organic revenue growth of 5% and EBITDA margin expansion of 40bps
• Expect strong FY 2026 earnings growth, with guidance of up to 19% EPS growth

Sonic Healthcare has reported strong financial results for the full year ended 30 June 2025, achieving its EBITDA earnings guidance. The company delivered 8% growth in both revenue and EBITDA, with organic revenue growth of 5% and normalised EBITDA margin expansion of 40bps. This was driven by organic growth and cost efficiency programs. Sonic expects strong earnings growth in FY 2026, with EBITDA guidance of A$1.87 - 1.95 billion (constant currency), equating to up to 19% EPS growth. The company's performance was underpinned by growth across its key markets, including the USA, Australia, Germany, Switzerland, and the UK. Sonic also completed several strategic acquisitions, including LADR in Germany and Cairo Diagnostics in the USA. The company is well-positioned for the future, with market-leading brands, experienced management, investment-grade credit metrics, and a strong medical leadership culture.

EBITDA guidance of A$1.87 - 1.95 billion (constant currency), equating to up to ~17% EBITDA growth on FY 2025 using current exchange rates. Depreciation expense expected to be in line with FY 2025, interest expense to increase by 15-20% (constant currency), and effective tax rate of ~27%.

Sonic Healthcare is well-positioned for the future, with significant competitive advantages including market-leading brands and positions, stable and experienced management, investment-grade credit metrics, and a strong medical leadership culture. The company is expecting strong EPS growth in FY 2026.